4.2 Review

Screening, evaluation and management of depression in people with diabetes in primary care

期刊

PRIMARY CARE DIABETES
卷 7, 期 1, 页码 1-10

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.pcd.2012.11.002

关键词

Diabetes mellitus; Depression; Diabetes distress; Screening; Primary care; Cognitive behavioral therapy

资金

  1. Eli Lilly
  2. Merck
  3. MSD
  4. Novo Nordisk
  5. Sanofi Aventis
  6. Takeda
  7. Bioton
  8. Servier
  9. NIHR CLAHRC
  10. Boehringer-Ingelheim
  11. Mannkind
  12. Pfizer
  13. Astra Zeneca
  14. Diabetes Research Foundation
  15. Lifescan

向作者/读者索取更多资源

Family physicians are responsible for diagnosing and treating the majority of people with type 2 diabetes mellitus and co-morbid depression. As a result of the impact of co-morbid depression on patient self-care and treatment outcomes, screening for depression in the context of a structured approach to case management and patient follow up is recommended in people with diabetes and cardiovascular disease. This review summarizes the need for improved recognition and treatment of depression in diabetes; and makes expert recommendations with regard to integrating screening tools and therapies into a busy family or general medical practice setting. (C) 2012 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据